ArticleBMC pulmonary medicine2026
When cough leads to infarction: systemic arterial embolism as a sentinel complication of insidious pulmonary mucormycosis in an immunocompetent patient.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPulmonary mucormycosis is a rapidly progressive and often fatal invasive fungal infection typically associated with immunocompromised states. However, its emergence in immunocompetent individuals is increasingly reported. This case describes an unusual presentation of pulmonary mucormycosis in an immunocompetent adult complicated by arterial embolism, a rare and life-threatening vascular manifestation. CASE PRESENTATION: We report the case of an immunocompetent adult patient presenting with persistent respiratory symptoms and radiological abnormalities. Despite the absence of conventional risk factors, the diagnosis was challenging due to nonspecific clinical features. The clinical course was further complicated by the development of an arterial embolism. The pathogen was successfully identified through metagenomic next-generation sequencing (mNGS), highlighting the utility of molecular diagnostic platforms for early detection in atypical hosts. The patient’s management required a combination of targeted antifungal therapy and intervention for the vascular complication.
conclusionsThis case underscores the shifting epidemiology of mucormycosis and the necessity of maintaining a high index of clinical suspicion even in patients without apparent immunodeficiency. It emphasizes the critical role of advanced diagnostic tools like mNGS in reducing delays in intervention for a disease with mortality rates exceeding 30%–50%. Further research is required to standardize diagnostic algorithms and management strategies for pulmonary mucormycosis in immunocompetent populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.